Table 1.

Clinicopathological characteristics.

	CCLR (n = 14)	CCDR (n = 8)	CCNR (n = 12)	p-valuea
Age	45.6 [32 – 69]	47.6 [37 – 60]	42.4 [32 – 61]	0.51
Histology				0.12
Squamous cell carcinoma	8 (57.1)	7 (87.5)	5 (41.7)
Adenocarcinoma	6 (42.9)	1 (12.5)	7 (68.3)
Surgical approach				<0.01
Laparotomy	14 (100.0)	8 (100.0)	3 (25.0)
Robot-assisted	0 (0.0)	0 (0.0)	9 (75.0)
LVSI				0.11
Yes	6 (42.9)	7 (87.5)	6 (50.0)
No	8 (57.1)	1 (12.5)	6 (50.0)
TNM stage, post-operative				<0.01
T1B1 N0 M0	14 (100)	2 (25.0)	12 (100)
T1B1 N1 M0	0 (0)	6 (75.0)	0 (0)
Adjuvant therapy				<0.01
Not indicated	12 (85.7)	0 (0.0)	10 (83.3)
Radiotherapy	2 (14.3)	6 (75.0)	2 (17.7)
Chemoradiation	0 (0.0)	2 (25.0)	0 (0.0)
HPV subtype
HPV-16	9* (69.2)	5 (62.5)	8 (66.7)
HPV-18	2 (15.4)	2 (25.0)	3 (25.0)
Other high-risk HPV	–	1 (12.5)	1 (8.3)
No HPV	2 (15.4)	–	–
Time to recurrence, months	17 [7-139]	39 [10-90]		0.48
Disease status last follow-up				<0.01
Alive, no evidence of disease	9 (64.3)	3 (37.5)	12 (100)
Dead with disease	5 (36.7)	5 (62.5)	0 (0)

Values are presented as numbers (%) or mean [range]. The numbers in bold are statistically significant. CCLR, Cervical cancer local recurrence; CCDR, Cervical cancer distant recurrence; CCNR, Cervical cancer no recurrence; FIGO, International Federation of Gynaecology and Obstetrics; LVSI, lymphovascular space invasion; TNM, Tumour Node Metastasis Classification of Malignant tumors. a Represents the P value between CCLR vs. CCDR vs. CCNR and the value in bold indicates a significant difference between the groups (p<0.05). *One patient was infected with both HPV-16 and HPV-18.

^aRepresents the p-value between CCLR vs. CCDR vs. CCNR and the value in bold indicates a significant difference between the groups (p < 0.05).